Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 3/20 | 0.82 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16592505 | 0.90 | PYGL (0.67) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL13964448 | 0.86 | HDAC1 (0.72) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11594592 | 0.86 | KCNMA1 (0.62) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11690428 | 0.85 | HDAC1 (0.63) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11692163 | 0.85 | PYGL (0.61) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11576194 | 0.83 | RAB9A (0.59) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11219138 | 0.82 | RAB9A (0.67) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL29459607 | 0.82 | RAB9A (0.67) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11574114 | 0.81 | PYGL (0.57) | PYGLHDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11319648 | 0.80 | HDAC1 (0.58) | PYGLHDAC8HDAC1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2509596-B1 | GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | disclosed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-11-06 | — | — | US | disclosed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| EP-2509596-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | Case Western Reserve University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | PYGL 1078/4885HDAC8 381/4885HDAC1 514/4885 |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | PYGL 470/4885HDAC8 1811/4885HDAC1 2353/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | PYGL 2495/4885HDAC8 2177/4885HDAC1 2022/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | PYGL 2495/4885HDAC8 2177/4885HDAC1 2022/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | PYGL 470/4885HDAC8 1811/4885HDAC1 2353/4885 |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | PYGL 470/4885HDAC8 1811/4885HDAC1 2353/4885 |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | PYGL 2440/4885HDAC8 826/4885HDAC1 483/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | PYGL 1078/4885HDAC8 381/4885HDAC1 514/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | PYGL 2440/4885HDAC8 826/4885HDAC1 483/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | PYGL 2440/4885HDAC8 826/4885HDAC1 483/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | PYGL 2495/4885HDAC8 2177/4885HDAC1 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.